Surface Oncology and Merck have entered into a clinical trial collaboration to evaluate the safety and efficacy of combining Surface’s SRF388, an investigational antibody therapy targeting IL-27, with Merck’s Keytruda (pembrolizumab), an anti-PD-1 therapy.
Last summer, Anirban Maitra, a pathologist specializing in pancreatic cancer, joined the NYU Langone Health Laura and Isaac Perlmutter Cancer Center to co-lead its Gastrointestinal Cancer Center.
